EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Revisiting tumor vasculature in the era of cancer immunotherapy: from aberrant hallmark to therapeutic target

Xiang Fang, Fanqi Wang, Haiman Li, Ping Xiao, Mengru Wang, Nan Wu, Xiaohong Yao, Yu Shi

Cancer Letters · 2026-11 · 660 · 218824

DOI: 10.1016/j.canlet.2026.218824 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2026-11. Verfasst von Xiang Fang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology & Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medic…. Hauptthemen laut MEDLINE: Neoplasms, Neovascularization, Pathologic, Immunotherapy, Angiogenesis Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 280 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Major Science and Technology Projects of China, Chongqing Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant angiogenesis is a hallmark of cancer that promotes tumor progression and therapeutic resistance. The resulting tumor vasculature is structurally and functionally abnormal, leading to inadequate perfusion and hypoxia. Beyond supporting tumor growth, such vascular abnormalities also restrict immune cell infiltration and impair antitumor immune responses. Accordingly, tumor vasculature emerges as a potential target to improve therapeutic outcomes. This review summarizes the cellular composition, functional heterogeneity, and diverse types of tumor vasculature, as well as the crosstalk between abnormal blood vessels and immune cells. We further outline the current vascular-targeting approaches, with a particular focus on their immunomodulatory effects and synergistic potential with immunotherapies. Diagnostic classification of tumor vasculature, together with the combination of vascular-targeted therapy and immunotherapy, may offer new opportunities for precision tumor treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsNeovascularization, PathologicImmunotherapyAngiogenesis InhibitorsHumansAnimalsTumor MicroenvironmentMolecular Targeted Therapy

Stichwörter der Autor:innen

Anti-angiogenic therapyImmunotherapyMacrophageTumor angiogenesisVascular normalization

Substanzen

Angiogenesis Inhibitors

Autor:innen und Institutionen

  • Institute of Pathology & Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laborat…
  • Department of Neurosurgery, Chongqing General Hospital, Chongqing University, Chongqing, 401147, China. Electronic address: wunan@cqu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • National Major Science and Technology Projects of China
  • Chongqing Municipal Health Commission

Zitieren

APA

Fang, X., Wang, F., Li, H., Xiao, P., Wang, M., Wu, N., Yao, X., & Shi, Y. (2026). Revisiting tumor vasculature in the era of cancer immunotherapy: from aberrant hallmark to therapeutic target. Cancer Letters, 660, 218824. https://doi.org/10.1016/j.canlet.2026.218824

Vancouver

Fang X, Wang F, Li H, Xiao P, Wang M, Wu N, et al. Revisiting tumor vasculature in the era of cancer immunotherapy: from aberrant hallmark to therapeutic target. Cancer Letters. 2026;660:218824. doi:10.1016/j.canlet.2026.218824

BibTeX
@article{Fang2026,
  author = {Fang, Xiang and Wang, Fanqi and Li, Haiman and Xiao, Ping and Wang, Mengru and Wu, Nan and Yao, Xiaohong and Shi, Yu},
  title = {Revisiting tumor vasculature in the era of cancer immunotherapy: from aberrant hallmark to therapeutic target},
  journal = {Cancer Letters},
  year = {2026},
  volume = {660},
  pages = {218824},
  doi = {10.1016/j.canlet.2026.218824}
}
Kostenlos starten →